Hypertension
Introduction
Hypertension (HTN) is a leading cause of premature death and disability in Canada and globally. For the MCCQE1, understanding hypertension is critical not only as an isolated diagnosis but as a major risk factor for cardiovascular disease (CVD), cerebrovascular disease, and chronic kidney disease (CKD).
In the Canadian context, approximately 1 in 4 adults has hypertension. The Medical Council of Canada (MCC) expects candidates to demonstrate competence in the screening, diagnosis, and management of hypertension according to current Hypertension Canada Guidelines.
Canadian Practice Note: Canada is a world leader in hypertension control. A unique feature of Canadian practice is the preference for Automated Office Blood Pressure (AOBP) over manual measurement to minimize the “white coat effect” and improve diagnostic accuracy.
Etiology and Classification
Hypertension is broadly classified into two categories:
1. Primary (Essential) Hypertension
- Accounts for 90–95% of cases.
- Pathophysiology: Multifactorial interplay of genetics, environment, and sympathetic nervous system/RAAS dysregulation.
- Risk Factors: Age, obesity, high sodium intake, alcohol, physical inactivity, family history, ethnicity (South Asian, African, and Indigenous populations in Canada are at higher risk).
2. Secondary Hypertension
- Accounts for 5–10% of cases.
- Suspect in patients who are young (<30), have resistant hypertension, or have sudden onset/worsening of BP.
MCCQE1 Mnemonic: Secondary Causes
Remember RENAAL:
- Renal (Renovascular disease, fibromuscular dysplasia)
- Endocrine (Hyperaldosteronism, Cushing’s, Pheochromocytoma, Hyperthyroidism)
- Neurological (Sleep apnea, increased ICP)
- Aortic (Coarctation)
- Alcohol / Drugs (NSAIDs, OCPs, Steroids, Cocaine)
- Little people (Pregnancy-induced / Preeclampsia)
Diagnosis and Screening
The diagnosis of hypertension in Canada relies heavily on the method of measurement. AOBP is the preferred method.
Diagnostic Thresholds
AOBP (Preferred)
Automated Office Blood Pressure (AOBP)
- Patient rests alone in a quiet room.
- Device takes multiple readings and averages them.
- Diagnostic Threshold: ≥ 135/85 mmHg
Diagnostic Algorithm (Hypertension Canada)
Step 1: Screening Visit
Perform BP measurement.
- If BP is markedly elevated (≥ 180/110 mmHg), diagnose HTN immediately.
- If BP is elevated but not emergent, proceed to Step 2.
Step 2: Out-of-Office Measurement
If the initial Office BP is elevated (130-179 / 85-109 mmHg):
- Order ABPM (Gold Standard) or HBPM (Series of measurements for 7 days).
- Alternative: If out-of-office measurement is not possible, serial office visits (OBP) can be used (3-5 visits).
Step 3: Confirm Diagnosis
Compare results to the specific thresholds for the measurement method used (see Tabs above).
Clinical Assessment
History
Focus on:
- Duration: Previous diagnoses or readings.
- Secondary Causes: Snoring (OSA), muscle weakness (Hyperaldosteronism), palpitations/sweating (Pheochromocytoma).
- Target Organ Damage (TOD): Chest pain (CAD), dyspnea (HF), visual changes (Retinopathy), claudication (PAD).
- Exogenous Substances: NSAIDs, oral contraceptives, decongestants, stimulants, alcohol.
Physical Examination
- Vitals: BP in both arms (discrepancy >20mmHg suggests subclavian stenosis or aortic dissection). BMI/Waist circumference.
- Fundoscopy: Hypertensive retinopathy (AV nicking, papilledema).
- Neck: Carotid bruits, JVP, thyroidomegaly.
- Cardiovascular: PMI displacement, S4 (LVH), murmurs.
- Abdomen: Renal bruits (Renovascular HTN), aortic pulsation.
- Extremities: Edema, pulses (radio-femoral delay suggests Coarctation).
Routine Investigations (Canadian Guidelines)
All patients with new hypertension should undergo a basic workup to screen for comorbidities, TOD, and secondary causes.
| Investigation | Rationale |
|---|---|
| Urinalysis | Screen for protein/blood (Renal disease). |
| Electrolytes (Na, K, Cl) | Baseline; hypokalemia may suggest hyperaldosteronism. |
| Creatinine / eGFR | Assess renal function (CKD). |
| Fasting Blood Glucose / HbA1c | Screen for Diabetes Mellitus. |
| Lipid Profile | Cardiovascular risk stratification. |
| 12-lead ECG | Screen for LVH, prior MI, or arrhythmia. |
Management
The goal of management is to reduce the risk of cardiovascular and renal complications.
Blood Pressure Targets
| Patient Population | Treatment Target (mmHg) |
|---|---|
| High Risk (SPRINT criteria: Age ≥50 + CVD risk factors) | Systolic < 120 |
| Diabetes Mellitus | < 130/80 |
| Low-Moderate Risk (Uncomplicated) | < 140/90 |
1. Health Behaviour Management
Before or alongside pharmacotherapy, all patients should be counseled on lifestyle changes.
- Diet: DASH diet (Dietary Approaches to Stop Hypertension).
- Sodium: Reduce intake to < 2000 mg/day (approx. 5g salt).
- Potassium: Increase dietary intake (unless CKD/hyperkalemia risk).
- Exercise: 30-60 mins of moderate dynamic exercise 4-7 days/week.
- Alcohol: Limit to ≤ 2 drinks/day (men) and ≤ 1 drink/day (women).
- Smoking: Cessation is mandatory for CVD risk reduction.
2. Pharmacotherapy
First-Line Agents for Uncomplicated HTN:
- Thiazide/Thiazide-like Diuretics (e.g., Chlorthalidone, Indapamide, Hydrochlorothiazide) - Long-acting preferred.
- ACE Inhibitors (ACEi) (e.g., Ramipril, Perindopril)
- Angiotensin Receptor Blockers (ARB) (e.g., Candesartan, Telmisartan)
- Calcium Channel Blockers (CCB) (e.g., Amlodipine)
Note: Beta-blockers are not indicated as first-line therapy for uncomplicated hypertension in patients ≥ 60 years of age unless there is a compelling indication (e.g., Heart Failure, post-MI).
Specific Indications (CanMEDS Medical Expert)
- Diabetes: ACEi or ARB (Renal protection).
- CKD (Albuminuria): ACEi or ARB.
- Coronary Artery Disease: ACEi/ARB + Beta-blocker (if post-MI).
- Heart Failure (HFrEF): ACEi/ARB/ARNI + Beta-blocker + MRA.
- Black Population: CCB or Thiazide-like diuretic preferred as initial monotherapy (unless diabetic/CKD).
3. Single Pill Combinations (SPC)
Hypertension Canada guidelines recommend considering Single Pill Combinations as initial therapy to improve adherence, especially if BP is >20/10 mmHg above target.
Key Points to Remember for MCCQE1
- AOBP is King: Know that AOBP threshold is 135/85, whereas manual is 140/90.
- SPRINT Trial: Be aware of the intensive target (SBP < 120) for high-risk cardiovascular patients.
- Diabetes Target: Strict control (< 130/80) is crucial.
- Hypertensive Urgency vs. Emergency:
- Urgency: BP > 180/120 without TOD. Manage with oral agents over days.
- Emergency: BP > 180/120 WITH acute Target Organ Damage (Encephalopathy, ACS, Acute HF, Aortic Dissection). Requires ICU and IV medications (e.g., Labetalol, Nitroprusside).
- Resistant Hypertension: Defined as failure to reach target on 3 drugs (including a diuretic) at optimal doses. Rule out secondary causes and non-adherence.
Sample Question
Clinical Scenario A 58-year-old male presents to your family practice clinic for a routine follow-up. He has a history of type 2 diabetes mellitus and dyslipidemia. He is currently taking Metformin and Atorvastatin. He is asymptomatic. His body mass index (BMI) is 31 kg/m².
During the visit, his Automated Office Blood Pressure (AOBP) is measured as 138/86 mmHg. A repeat measurement 5 minutes later confirms a similar reading. His heart rate is 72 bpm and regular. Physical examination is otherwise unremarkable. Urinalysis shows no proteinuria.
Question According to Hypertension Canada guidelines, which of the following is the most appropriate next step in the management of this patient?
Detailed Analysis
- Diagnosis: This patient has Type 2 Diabetes. For patients with diabetes, the diagnostic threshold for hypertension using AOBP is ≥ 130/80 mmHg (Hypertension Canada Guidelines). This patient’s BP is 138/86 mmHg, which confirms the diagnosis of hypertension in this specific population.
- Treatment Threshold: In patients with diabetes, antihypertensive therapy should be initiated if BP is consistently ≥ 130/80 mmHg.
- Drug Choice:
- First-line for Diabetes: ACE Inhibitors (ACEi) or ARBs are the preferred initial agents because of their renoprotective effects (slowing progression of nephropathy).
- Dihydropyridine CCBs (Option C) are also first-line agents but are generally second-choice to ACEi/ARB in diabetics unless there are specific contraindications or if dual therapy is needed.
- Why not Lifestyle alone (Option B)? While lifestyle modification is crucial, this patient is already above the treatment threshold for his risk profile (Diabetes). Delaying pharmacological treatment is not recommended when the patient is already hypertensive by diabetic standards.
- Why not ABPM (Option E)? While ABPM is the gold standard for diagnosis, in a patient with diabetes and AOBP clearly above the threshold (130/80), delaying treatment to confirm what is already a diagnostic reading in a high-risk patient is generally not necessary, though not strictly “wrong” in all contexts. However, initiating treatment (D) is the most appropriate action to reduce risk.
- Why not Reassess (Option A)? This would leave a high-risk patient untreated.
Summary: In a diabetic patient with BP > 130/80 mmHg, immediate initiation of an ACE inhibitor or ARB is the standard of care in Canada.
Canadian Guidelines
This content aligns with the Hypertension Canada Guidelines (2020-2022).
- Screening: All adults should have BP assessed at all appropriate clinical visits.
- Diagnosis: AOBP is the preferred method.
- Adherence: Single Pill Combinations (SPC) are recommended to improve adherence.
- Follow-up: Once target is reached, follow up every 3-6 months.
References
- Rabi DM, McBrien K, Sapir-Pichhadze R, et al. Hypertension Canada’s 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. Can J Cardiol. 2020;36(5):596-624. Link to Guidelines
- Leung AA, Daskalopoulou SS, Dasgupta K, et al. Hypertension Canada’s 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. Can J Cardiol. 2017;33(5):557-576.
- Medical Council of Canada. Objectives for the Qualifying Examination Part I. MCC.ca
- Whelton PK, et al. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-16.